earnings
The GLP-1 Gap Is Widening: What Q2 Says About Lilly and Novo
Eli Lilly grew Q2 revenue 48% while Novo Nordisk's adjusted sales rose 7% at CER. Here is what the divergence means for investors.
NYSE · Pharmaceuticals
Novo Nordisk A/S (NVO)
Novo Nordisk is a global pharmaceutical company best known for diabetes and obesity medicines based on GLP-1 therapies. Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S employs approximately 77,000 people.
Reference price$246.40
Daily change-1.95%
Market cap$220B
P/E ratio—
Analyst consensusPending market sync
Price target$275.97
Next earningsPending market sync
Dividend yield3.80%
Company profile
Headquarters
Founded
1923
Employees
77,000
Related coverage